Details

Prodrugs and Targeted Delivery


Prodrugs and Targeted Delivery

Towards Better ADME Properties
Methods and Principles in Medicinal Chemistry, Band 47 1. Aufl.

von: Jarkko Rautio, Raimund Mannhold, Hugo Kubinyi, Gerd Folkers

156,99 €

Verlag: Wiley-VCH
Format: EPUB
Veröffentl.: 11.01.2011
ISBN/EAN: 9783527633180
Sprache: englisch
Anzahl Seiten: 520

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies for the rational design of prodrugs, beginning at the early stages of the development process, as well as discussing organ- and site-selective prodrugs. <br> Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development.<br>
Preface<br> <br> PART ONE: Prodrug Design and Intellectual Property<br> <br> PRODRUG STRATEGIES IN DRUG DESIGN<br> Prodrug Concept<br> Basics of Prodrug Design<br> Rationale for Prodrug Design<br> History of Prodrug Design<br> Recently Marketed Prodrugs<br> Concluding Remarks<br> <br> THE MOLECULAR DESIGN OF PRODRUGS BY FUNCTIONAL GROUP<br> Introduction<br> The Prodrug Concept and Basics of Design<br> Common Functional Group Approaches in Prodrug Design<br> Conclusions<br> <br> INTELLECTUAL PROPERTY PRIMER ON PHRAMACEUTICAL PATENTS WITH A SPECIAL EMPHASIS ON PRODRUGS AND METABOLITES<br> Introduction<br> Patents and FDA Approval Process<br> Obtaining a Patent<br> Conclusion<br> <br> PART TWO: Prodrugs Addressing ADMET Issues<br> <br> INCREADING LIPOPHILICITY FOR ORAL DRUG DELIVERY<br> Introduction<br> pKa, Degree of Ionization, Partition Coefficient, and Distribution Coefficient<br> Prodrug Strategies to Enhance Lipid Solubility<br> Prodrug Examples for Antibiotics<br> Antiviral Related Prodrugs<br> Cardiovascular Related Prodrugs<br> Lipophilic Prodrugs of Benzamidine Drugs<br> Miscellaneous Examples<br> Summary and Conclusion<br> <br> MODULATING SOLUBILITY THROUGH PRODRUGS FOR ORAL AND IV DRUG DELIVERY<br> Introduction<br> Basics of Solubility and Oral/IV Drug Delivery<br> Prodrug Applications for Enhanced Aqueous Solubility<br> Challenges with Solubilizing Prodrugs of Insoluble Drugs<br> Additional Applications of Prodrugs for Modulating Solubility<br> Parallel Exploration of Analogues and Prodrugs in Drug Discovery (Commentary)<br> Conclusions<br> <br> PRODRUGS DESIGNED TO TARGET TRANSPORTERS FOR ORAL DRUG DELIVERY<br> Introduction<br> Serendipity: An Actively Transported Prodrug<br> Requirements for Actively Transported Prodrugs<br> Peptide Transporters: PEPT1 and PEPT2<br> Monocarboxylate Transporters<br> Bile Acid Transporters<br> Conclusions<br> <br> TOPICAL AND TRANSDERMAL DELIVERY USING PRODRUGS: MECHANISM OF ENHANCEMENT<br> Introduction<br> Arrangement of Water in the Stratum Corneum<br> A New Model for Diffusion Through the Stratum Corneum: The Biphasic Solubility Model<br> Equations for Quantifying Effects of Solubility on Diffusion Through the Stratum Corneum<br> Design of Prodrugs for Topical and Transdermal Delivery Based on the Biphasic Solubility Model<br> Comparison of Human and Mouse Skin Experiments<br> Summary<br> <br> OCULAR DELIVERY USING PRODRUGS<br> Introduction<br> Criteria for an Ideal Ophthalmic Prodrug<br> Anatomy and Physiology of the Eye<br> Barriers to Ocular Drug Delivery<br> Influx and Efflux Transporters on the Eye<br> Transporter-Targeted Prodrug Approach<br> Drug Disposition in Ocular Delivery<br> Effect of Physiochemical Factors on Drug Disposition in Eye<br> Prodrug Strategy to Improve Ocular Bioavailability (Nontransporter-Targeted Approach)<br> Recent Patents and Marketed Ocular Prodrugs<br> Novel Formulation Approaches for Sustained Delivery of Prodrugs<br> Conclusion<br> <br> REDUCING PRESYSTEMIC DRUG METABOLISM<br> Introduction<br> Presystemic Metabolic Barriers<br> Prodrug Approaches to Reduce Presystemic Drug Metabolism<br> Targeting Colon<br> Targeting Lymphatic Route<br> Conclusion<br> <br> ENZYME-ACTIVATED PRODRUG STRATEGIES FOR SITE-SELECTIVE DRUG DELIVERY<br> Introduction<br> General Requirements for Enzyme-Activated Targeted Prodrug Strategy<br> Examples of Targeted Prodrug Strategies<br> Summary<br> <br> PRODRUG APPROACHES FOR CENTRAL NERVOUS SYSTEM DELIVERY<br> Blood-Brain Barrier in CNS Drug Development<br> Prodrug Strategies<br> Prodrug Strategies Based Upon BBB Nutrient Transporters<br> Prodrug Strategies Based Upon BBB Receptors<br> CNS Prodrug Summary<br> <br> DIRECTED ENZYME PRODRUG THERAPIES<br> Introduction<br> Theoretical Background of DEPT<br> Comparison of ADEPT and GDEPT<br> Enzymes in ADEPT and GDEPT<br> Design of Prodrugs<br> Strategies Used for the Improvement of DEPT Systems<br> Biological Data for ADEPT and GDEPT<br> Conclusions<br> <br> PART THREE: Codrugs and Soft Drugs<br> <br> IMPROVING THE USE OF DRUG COMBINATIONS THROUGH THE CODRUG APPROACH<br> Codrugs and Codrug Strategy<br> Ideal Codrug Characteristics<br> Examples of Marketed Codrugs<br> Topical Codrug Therapy for the Treatment of Ophthalmic Diseases<br> Codrugs for Transdermal Delivery<br> Codrugs of L-DOPA for the Treatment of Parkinson's Disease<br> Analgesic Codrugs Containing Nonsteroidal Anti-Inflammatory Agents<br> Analgesic Codrugs of Opioids and Cannabinoids<br> Codrugs Containing Anti-HIV Drugs<br> <br> SOFT DRUGS<br> Introduction<br> Indications<br> Design Considerations<br> Case Study: The Discovery of Esmolol<br> Summary<br> <br> PART FOUR: Preclinical and Clinical Considerations for Prodrugs<br> <br> PHARMACOKINETIC AND BIOPHARMACEUTICAL CONSIDERATIONS IN PRODRUG DISCOVERY AND DEVELOPMENT<br> Introduction<br> Understanding Pharmacokinetic/Pharmacodynamic Relationships<br> Pharmacokinetics<br> Tools for the Prodrug Scientist<br> Enzymes Involved with Prodrug Conversion<br> Use of the Caco-2 System for Permeability and Active Transport Evaluation<br> XP13512: Improving PK Performance by Targeting Active Transport<br> Prodrug Absorption: Transport/Metabolic Conversion Interplay<br> Preabsorptive Degradation<br> Biopharmaceutical-Based PK Modeling for Prodrug Design<br> Conclusions<br> <br> THE IMPACT OF PHARMACOGENETICS ON THE CLINICAL OUTCOMES OF PRODRUGS<br> Introduction<br> Clopidogrel and CYP2C19<br> Codeine and CYP2D6<br> Tamoxifen and CYP2D6<br> Fluorouracil Prodrugs and Carboxylesterase<br> Irinotecan and Carboxylesterase 2<br> Others<br> Drug Development Implication<br> Conclusions<br> <br> <br> <br> <br> <br> <br>
"The book captures all the important aspects of prodrugs. It is well organized in that each chapter presents a specific topic with very little duplication of contents between chapters . . . Given the fact that prodrugs are now increasingly integrated into early drug discovery, this type of book would be a valuable addition to the library of any drug discovery institution." (Journal of Medicinal Chemistry, 8 August 2011) <p> "Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development." (Pharmiweb, 16 February 2011)</p>
Jarkko Rautio is professor of pharmaceutical chemistry and head of the multidisciplinary Pharmaceutical and Medicinal Chemistry (PMC) research group at the School of Pharmacy, University of Eastern Finland (formerly University of Kuopio), where he received his PhD in pharmaceutical chemistry in 2000. He subsequently carried out his postdoctoral studies at the University of Maryland, Baltimore, USA, and was a visiting scientist at GlaxoSmithKline, North Carolina, while also co-founding the American Association of Pharmaceutical Scientists (AAPS) Prodrug Focus Group in 2005. Professor Rautio's research focuses on chemistry-based methods, especially prodrugs, to overcome the liabilities of drugs.
By definition, drugs are highly active substances that are beneficial if they act at the right time and in the right place, but can cause harm otherwise. A clever strategy to ensure that a drug only becomes active when needed is to "camouflage" it. Such camouflaged, i.e. deactivated, drugs that become chemically or biochemically activated once they reach their site of action are called prodrugs.<br> <br> This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies, beginning at the early stages of the development process, while also discussing organ- and site-selective prodrugs. <br> <br> From the contents:<br> * Prodrug design and intellectual property <br> * Prodrugs addressing ADMET issues<br> * Codrugs and soft drugs<br> * Preclinical and clinical consideration for prodrugs<br> <br> This book is a valuable reference for all companies employing medicinal chemists by giving a practice-oriented overview of a key strategy in modern drug discovery and development.<br>

Diese Produkte könnten Sie auch interessieren:

Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
PDF ebook
126,99 €
Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
EPUB ebook
126,99 €
Kunststoffe
Kunststoffe
von: Wilhelm Keim
PDF ebook
99,99 €